Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jeremy A Ross

Showing results (71-80 of 75) with videos related to

Pageof 8
Sort By:
You have reached the last page of results.This site can display upto 75 results.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 10, 2025
Venetoclax-Dexamethasone Versus Pomalidomide-Dexamethasone in t(11;14)-Positive Relapsed/Refractory Multiple Myeloma: Primary Results of the Randomized, Phase III CANOVA StudyRakesh Popat, Meral Beksac, Meletios A Dimopoulos, et al.
Cancer Discovery|February 17, 2021
Venetoclax and Navitoclax in Combination with Chemotherapy in Patients with Relapsed or Refractory Acute Lymphoblastic Leukemia and Lymphoblastic LymphomaVinod A Pullarkat, Norman J Lacayo, Elias Jabbour, et al.
Pediatric Blood & Cancer|April 23, 2025
Venetoclax Alone or in Combination With Chemotherapy in Paediatric and Adolescent/Young Adult Patients With Relapsed/Refractory Acute Myeloid LeukaemiaSeth E Karol, Seong L Khaw, C Michel Zwaan, et al.
Blood Advances|August 19, 2025
Prospective real-world evaluation of t(11;14) prevalence and disease biology in multiple myeloma: MEDICI study analysisAndrew Spencer, Maria Gavriatopoulou, Daniel Coriu, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 29, 2021
Minimal Residual Disease in Myeloma: Application for Clinical Care and New Drug RegistrationKenneth C Anderson, Daniel Auclair, Stacey J Adam, et al.
Pageof 8

Showing results (71-80 of 75) with videos related to

Sort By:
Pageof 8
You have reached the last page of results.This site can display upto 75 results.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 10, 2025
Venetoclax-Dexamethasone Versus Pomalidomide-Dexamethasone in t(11;14)-Positive Relapsed/Refractory Multiple Myeloma: Primary Results of the Randomized, Phase III CANOVA StudyRakesh Popat, Meral Beksac, Meletios A Dimopoulos, et al.
Cancer Discovery|February 17, 2021
Venetoclax and Navitoclax in Combination with Chemotherapy in Patients with Relapsed or Refractory Acute Lymphoblastic Leukemia and Lymphoblastic LymphomaVinod A Pullarkat, Norman J Lacayo, Elias Jabbour, et al.
Pediatric Blood & Cancer|April 23, 2025
Venetoclax Alone or in Combination With Chemotherapy in Paediatric and Adolescent/Young Adult Patients With Relapsed/Refractory Acute Myeloid LeukaemiaSeth E Karol, Seong L Khaw, C Michel Zwaan, et al.
Blood Advances|August 19, 2025
Prospective real-world evaluation of t(11;14) prevalence and disease biology in multiple myeloma: MEDICI study analysisAndrew Spencer, Maria Gavriatopoulou, Daniel Coriu, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 29, 2021
Minimal Residual Disease in Myeloma: Application for Clinical Care and New Drug RegistrationKenneth C Anderson, Daniel Auclair, Stacey J Adam, et al.
Pageof 8